Early physicochemical properties of interest for pharmaceutical drugability can only be evaluated with very small bulk quantities available at the first stages of research. Our small-scale methodologies allow rapid assessment of these specific properties in the correct way, in order to be able to quickly bring forward relevant data to help select the best chemical series and compounds at the in vitro stage.

When it comes to lead optimisation and drug candidate selection, physicochemical properties cannot be decorrelated from minimal physical characterisations of the solid state of the studied bulks. We therefore start combining at that stage small scale methodologies for assessing the first few physical characteristics of interest, to the measured physicochemical properties, but also taking into account the desired Target Product Profile.

When launching the preclinical development studies for a new drug candidate, the physicochemical and physical properties of the available bulk must be precisely characterised. Solubility and stability profiles of the API, as well as the impact of the API solid state on them or on the chosen drug delivery options are studied in our labs and are fully described.